Query: stroke

Filtered By:
Condition: Heart Failure
Condition1: Pulmonary Hypertension

This page shows you your search results in order of date.

Order by Relevance | Date

Total 116 results found since Jan 2013.

MILLER Banding Procedure for Treatment of Dialysis Access-Related Steal Syndrome, Pulmonary Hypertension, and Heart Failure
Am Surg. 2021 Nov 18:31348211056259. doi: 10.1177/00031348211056259. Online ahead of print.ABSTRACTA Minimally Invasive Limited Ligation Endoluminal-assisted Revision (MILLER) banding procedure has been used for treating patients with dialysis access-related steal syndrome (DASS) and high-flow vascular access-related pulmonary hypertension (PHT) and heart failure (HF).We performed a retrospective analysis of patients undergoing the MILLER procedure performed for DASS, HF, and PHT from our Vascular Access Database from September 2017 to October 2019. Outcomes included primary patency of banding, primary assisted patency, an...
Source: The American Surgeon - November 19, 2021 Category: Surgery Authors: Ahmad Alqassieh Patrick B Dennis Veena Mehta June Shi Angello Lin Dave Taber Vinayak Rohan Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Right ventricular and cyclic guanosine monophosphate signalling abnormalities in stages B and C of heart failure with preserved ejection fraction
ConclusionExercise CMR identifies impaired RV-arterial coupling at an early stage of HFpEF. Circulating cGMP levels phenocopy the haemodynamic spectrum in HFpEF but fail to increase after phosphodiesterase type 5 inhibition, endorsing the need for alternative interventions to increase cGMP signalling in HFpEF.
Source: ESC Heart Failure - September 3, 2021 Category: Cardiology Authors: Thibault Petit, Guido Claessen, Mathias Claeys, Andre La Gerche, Piet Claus, Stefan Ghysels, Marion Delcroix, Agnieszka Ciarka, Walter Droogne, Johan Van Cleemput, Rik Willems, Jens ‐Uwe Voigt, Jan Bogaert, Stefan Janssens Tags: Original Research Article Source Type: research

Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Curr Pharm Des. 2021 Sep 2. doi: 10.2174/1381612827666210902152539. Online ahead of print.ABSTRACTVenous thromboembolism clinically presents as deep venous thrombosis or acute pulmonary embolism and is globally recognized as the third most frequent acute cardiovascular syndrome after myocardial infarction and stroke. Although pulmonary embolism does not typically cause severe pulmonary hypertension in the acute setting, thrombus organization and fibrosis can lead to stenosis or obliteration of pulmonary arteries in a minority of patients, which in turn result in severe pulmonary hypertension and right heart failure. This d...
Source: Current Pharmaceutical Design - September 3, 2021 Category: Drugs & Pharmacology Authors: Nikolaos Papakonstantinou Polydoros Kampaktsis Filippos-Paschalis Rorris Ilias Doulamis Aspasia Tzani Sotirios Katsaridis Dimitrios Avgerinos Source Type: research

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Circulation. 2021 Jun 21:CIR0000000000000988. doi: 10.1161/CIR.0000000000000988. Online ahead of print.ABSTRACTObstructive sleep apnea (OSA) is characterized by recurrent complete and partial upper airway obstructive events, resulting in intermittent hypoxemia, autonomic fluctuation, and sleep fragmentation. Approximately 34% and 17% of middle-aged men and women, respectively, meet the diagnostic criteria for OSA. Sleep disturbances are common and underdiagnosed among middle-aged and older adults, and the prevalence varies by race/ethnicity, sex, and obesity status. OSA prevalence is as high as 40% to 80% in patients with ...
Source: Circulation - June 21, 2021 Category: Cardiology Authors: Yerem Yeghiazarians Hani Jneid Jeremy R Tietjens Susan Redline Devin L Brown Nabil El-Sherif Reena Mehra Biykem Bozkurt Chiadi Ericson Ndumele Virend K Somers American Heart Association Council on Clinical Cardiology; Council on Peripheral Vascular Diseas Source Type: research

Combined brain/heart magnetic resonance imaging in antiphospholipid syndrome-two sides of the same coin
AbstractAntiphospholipid syndrome (APS) is an autoimmune disorder characterized by arterial, venous, and/or small vessel thrombosis, pregnancy morbidity, and persistently elevated levels of antiphospholipid antibodies (aPL). Cardiovascular disease (CVD) in APS can present as heart valvular disease (HVD), macro-micro-coronary artery disease (CAD), myocardial dysfunction, cardiac thrombi, or pulmonary hypertension. Brain disease presents as stroke or transient ischemic attack (TIA) and less frequently as cerebral venous thrombosis, seizures, cognitive dysfunction, multiple sclerosis (MS) −like syndrome, or chorea. Infarcts...
Source: Clinical Rheumatology - June 10, 2021 Category: Rheumatology Source Type: research

Cardiovascular magnetic resonance predicts all-cause mortality in pulmonary hypertension associated with heart failure with preserved ejection fraction
This study aimed to determine the prognostic value of cardiovascular magnetic resonance (CMR) in patients with heart failure with preserved ejection fraction and associated pulmonary hypertension (pulmonary hypertension-HFpEF). Patients with pulmonary hypertension-HFpEF were recruited from the ASPIRE registry and underwent right heart catheterisation (RHC) and CMR. On RHC, the inclusion criteria was a mean pulmonary artery pressure (MPAP)  ≥ 25 mmHg and pulmonary arterial wedge pressure >  15 mmHg and, on CMR, a left atrial volume >  41 ml/m2 with left ventricular ejection fraction  >  50%. Cox r...
Source: The International Journal of Cardiovascular Imaging - May 12, 2021 Category: Radiology Source Type: research

Inhibition of mTOR by rapamycin does not improve hypoxic pulmonary hypertension-induced right heart failure in old mice
Exp Gerontol. 2021 May 7:111395. doi: 10.1016/j.exger.2021.111395. Online ahead of print.ABSTRACTInhibition of the mammalian target of rapamycin (mTOR) by rapamycin attenuates heart failure (HF) and age-associated changes in left ventricular (LV) function. Rapamycin has also been suggested as a therapy for pulmonary hypertension (PH) and concomitant right heart failure (PH-RHF) based on reports of elevated mTOR signaling in young models with PH. However, rapamycin has yet to be tested in the setting of aging, PH, and right heart disease despite the fact that RV function predicts survival in both age-related HF as well as s...
Source: Experimental Gerontology - May 10, 2021 Category: Geriatrics Authors: Benjamin D McNair Jacob A Schlatter Ross F Cook Musharraf Yusifova Danielle R Bruns Source Type: research

Predictors and prognosis of right ventricular function in pulmonary hypertension due to heart failure with reduced ejection fraction
ConclusionsThe RV ‐PA coupling ratio Ees/Ea predicts overall survival in PH due to HFREF and is mainly affected by pulsatile load, RV remodelling, and left ventricular dysfunction. Prognostically favourable coupling (RV‐Ees/Ea ≥ 0.68) in PH was associated with preserved RV size/function and mid‐term surviva l, comparable with HFREF without PH.
Source: ESC Heart Failure - May 2, 2021 Category: Cardiology Authors: Alexander Schmei ßer, Thomas Rauwolf, Thomas Groscheck, Katharina Fischbach, Siegfried Kropf, Blerim Luani, Ivan Tanev, Michael Hansen, Saskia Meißler, Kerstin Schäfer, Paul Steendijk, Ruediger C. Braun‐Dullaeus Tags: Original Research Article Source Type: research

Sildenafil Administration Improves Right Ventricular Function on 4D Flow MRI in Young Adults Born Premature
CONCLUSIONS: Despite reduced right atrial workload, metoprolol significantly depressed overall cardiac systolic function. Sildenafil, however, increased CI and improved RV function, as quantified by the direct flow fraction. The preterm heart appears dependent on HR, but sensitive to RV afterload manipulations.PMID:33861148 | DOI:10.1152/ajpheart.00824.2020
Source: American Journal of Physiology. Heart and Circulatory Physiology - April 16, 2021 Category: Physiology Authors: Philip A Corrado Gregory P Barton Christopher J Fran çois Oliver Wieben Kara N Goss Source Type: research

Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension
ConclusionsPlasma prolargin levels differentiate PAH patients from controls and the other investigated dyspnoea groups including HF. Its potential in PAH differentiation may be enhanced by inclusion in a multi ‐marker panel. Larger studies are needed to evaluate its discriminative ability of PAH in relation to other dyspnoea aetiologies and its potential role in PAH risk stratification and pathobiology.
Source: ESC Heart Failure - March 29, 2021 Category: Cardiology Authors: Mattias Arvidsson, Abdulla Ahmed, Habib Bouzina, G öran Rådegran Tags: Original Research Article Source Type: research

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Routine preoperative resting echocardiography does not predict adverse cardiopulmonary events after bariatric surgery
CONCLUSION: A routine resting preoperative echocardiography added little to the cardiopulmonary risk stratification of patients who underwent bariatric surgery. High-risk patients were identifiable based on their medical history, particularly those with a known history of coronary artery disease and coronary revascularization.PMID:33637417 | DOI:10.1016/j.soard.2021.01.021
Source: Surgery for Obesity and Related Diseases : official journal of the American Society for Bariatric Surgery - February 27, 2021 Category: Surgery Authors: Kiavash Koko Jonathan T Carter Source Type: research

Comparison of levosimendan, NO, and inhaled iloprost for pulmonary hypertension reversibility assessment in heart transplant candidates
ConclusionsLevosimendan may be a safe and effective alternative for pulmonary hypertension reversibility assessment or a valuable pre ‐test medical optimization tool in end‐stage heart failure patient assessment for heart transplantation offering extended haemodynamic benefits. Whether it increases the rate of positive responses or allows a better selection of candidates to heart transplantation remains to be established.
Source: ESC Heart Failure - February 23, 2021 Category: Cardiology Authors: Marta Tavares ‐Silva, Francisca Saraiva, Roberto Pinto, Sandra Amorim, João Carlos Silva, Adelino F. Leite‐Moreira, Maria Júlia Maciel, André P. Lourenço Tags: Original Research Article Source Type: research

Prognostic value of the H2FPEF score in patients undergoing transcatheter aortic valve implantation
ConclusionsThe H2FPEF score serves as an independent predictor of adverse CV and heart failure outcome among TAVI patients with preserved EF. A high H2FPEF score is associated with the presence of paradoxical low ‐flow, low‐gradient AS, the HFpEF in patients with AS. By identifying patients in advanced stages of HFpEF, the H2FPEF score might be useful as a risk prediction tool in patients with preserved EF scheduled for TAVI.
Source: ESC Heart Failure - January 25, 2021 Category: Cardiology Authors: Sebastian Ludwig, Costanza Pellegrini, Alina Gossling, Tobias Rheude, Lisa Voigtl änder, Oliver D. Bhadra, Matthias Linder, Daniel Kalbacher, Benedikt Koell, Lara Waldschmidt, Johannes Schirmer, Moritz Seiffert, Hermann Reichenspurner, Stefa Tags: Original Research Article Source Type: research

Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension
ConclusionsPlasma prolargin levels differentiate PAH patients from controls and the other investigated dyspnoea groups including HF. Its potential in PAH differentiation may be enhanced by inclusion in a multi ‐marker panel. Larger studies are needed to evaluate its discriminative ability of PAH in relation to other dyspnoea aetiologies and its potential role in PAH risk stratification and pathobiology.
Source: ESC Heart Failure - January 5, 2021 Category: Cardiology Authors: Mattias Arvidsson, Abdulla Ahmed, Habib Bouzina, G öran Rådegran Tags: Original Research Article Source Type: research

Prognostic value of the H2FPEF score in patients undergoing transcatheter aortic valve implantation
ConclusionsThe H2FPEF score serves as an independent predictor of adverse CV and heart failure outcome among TAVI patients with preserved EF. A high H2FPEF score is associated with the presence of paradoxical low ‐flow, low‐gradient AS, the HFpEF in patients with AS. By identifying patients in advanced stages of HFpEF, the H2FPEF score might be useful as a risk prediction tool in patients with preserved EF scheduled for TAVI.
Source: ESC Heart Failure - November 20, 2020 Category: Cardiology Authors: Sebastian Ludwig, Costanza Pellegrini, Alina Gossling, Tobias Rheude, Lisa Voigtl änder, Oliver D. Bhadra, Matthias Linder, Daniel Kalbacher, Benedikt Koell, Lara Waldschmidt, Johannes Schirmer, Moritz Seiffert, Hermann Reichenspurner, Stefa Tags: Original Research Article Source Type: research

Systemic vascular distensibility relates to exercise capacity in connective tissue disease
ConclusionSystemic vascular distensibility, α is associated with impaired systemic oxygen extraction and decreased aerobic capacity in patients with CTD without cardiopulmonary disease.
Source: Rheumatology - October 1, 2020 Category: Rheumatology Source Type: research

Evaluating the impact of chronic obstructive pulmonary disease on in ‐hospital outcomes following left ventricular assist device implantation
ConclusionPatients with COPD undergoing LVAD implantation have more comorbidities, without an associated increase mortality.
Source: Journal of Cardiac Surgery - September 30, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Bertrand Ebner, Jelani K. Grant, Louis Vincent, Jennifer Maning, Neal Olarte, Odunayo Olorunfemi, Rosario Colombo, Sandra Chaparro Tags: ORIGINAL ARTICLE Source Type: research

The effect of Riociguat on cardiovascular function and efficiency in healthy, juvenile pigs
DiscussionInfusion of 100  µg/kg Riociguat gave modest systemic vasodilatation seen as a drop in coronary and systemic vascular resistance of 36% and 26%, respectively. Right and left ventriculoarterial coupling index (Ees/Ea), stroke work efficiency (SWeff), and the relationship between left ventricular myocardial oxygen consumption (MVO2) and total mechanical work (pressure –volume area; PVA) were unaffected by Riociguat. In contrast, systemic and pulmonary vasoconstriction induced by L‐NAME (15 mg/kg) shifted the Ees/Ea ratio toward reduced SWeff in both systemic and pulmonary circulation. However, there was no s...
Source: Physiological Reports - September 11, 2020 Category: Physiology Authors: Torvind N æsheim, Ole‐Jakob How, Truls Myrmel Tags: ORIGINAL RESEARCH Source Type: research

Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients  - A Randomized Controlled Trial.
CONCLUSIONS: Dapagliflozin significantly improved RVSP and LVFP during exercise in patients with T2DM and cardiovascular risk, which may contribute to favorable effects on heart failure. PMID: 32921680 [PubMed - as supplied by publisher]
Source: Circulation Journal - September 11, 2020 Category: Cardiology Authors: Kayano H, Koba S, Hirano T, Matsui T, Fukuoka H, Tsuijita H, Tsukamoto S, Hayashi T, Toshida T, Watanabe N, Hamazaki Y, Geshi E, Murakami M, Aihara K, Kaneko K, Yamada H, Kobayashi Y, Shinke T Tags: Circ J Source Type: research

The effect of Riociguat on cardiovascular function and efficiency in healthy, juvenile pigs
DiscussionInfusion of 100  µg/kg Riociguat gave modest systemic vasodilatation seen as a drop in coronary and systemic vascular resistance of 36% and 26%, respectively. Right and left ventriculoarterial coupling index (Ees/Ea), stroke work efficiency (SWeff), and the relationship between left ventricular myocardial oxygen consumption (MVO2) and total mechanical work (pressure –volume area; PVA) were unaffected by Riociguat. In contrast, systemic and pulmonary vasoconstriction induced by L‐NAME (15 mg/kg) shifted the Ees/Ea ratio toward reduced SWeff in both systemic and pulmonary circulation. However, there was no s...
Source: Physiological Reports - September 11, 2020 Category: Physiology Authors: Torvind N æsheim, Ole‐Jakob How, Truls Myrmel Tags: ORIGINAL RESEARCH Source Type: research

Prognostic Implications of Significant Isolated Tricuspid Regurgitation in Patients With Atrial Fibrillation Without Left-Sided Heart Disease or Pulmonary Hypertension
The prognostic impact of isolated tricuspid regurgitation (TR) in patients with atrial fibrillation (AF) has not been investigated. The purpose of this study was to investigate the prognostic implications of significant isolated TR in AF patients without left-sided heart disease, pulmonary hypertension or primary structural abnormalities of the tricuspid valve.A total of 63 AF patients with moderate and severe TR were matched for age and gender to 116 AF patients without significant TR. Patients were followed for the occurrhttps://doi.org/10.13039/100006520ence of all-cause mortality, hospitalization for heart failure and stroke.
Source: The American Journal of Cardiology - August 27, 2020 Category: Cardiology Authors: Marlieke F Dietz, Laurien Goedemans, N Mai Vo, Edgard A Prihadi, Pieter van der Bijl, Bernard J Gersh, Nina Ajmone Marsan, Victoria Delgado, Jeroen J Bax Source Type: research

Elevated plasma endocan and BOC in heart failure patients decrease after heart transplantation in association with improved hemodynamics
ConclusionOur results suggest that (i) plasma endocan in HF may reflect the state of pulmonary vascular congestion and PH-LHD, whereas (ii) plasma BOC may reflect the cardiac function and the hemodynamic overload  in HF. The exact role of these proteins and their clinical applicability as biomarkers in HF and PH-LHD ought to be investigated in larger cohorts.
Source: Heart and Vessels - July 9, 2020 Category: Cardiology Source Type: research

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Women's Participation in Cardiovascular Clinical Trials From 2010 to 2017.
CONCLUSIONS: Among cardiovascular trials in the current decade, men still predominate overall, but the representation of women varies with disease and trial characteristics, and has improved in stroke and heart failure trials. PMID: 32065763 [PubMed - in process]
Source: Circulation - February 17, 2020 Category: Cardiology Authors: Jin X, Chandramouli C, Allocco B, Gong E, Lam CSP, Yan LL Tags: Circulation Source Type: research

Obstructive sleep apnea and cardiac mechanics: how strain could help us?
AbstractObstructive sleep apnea (OSA) syndrome is the most common sleep-breathing disorder, which is associated with increase cardiovascular morbidity and mortality. OSA increases risk of resistant arterial hypertension, coronary artery disease, heart failure, pulmonary hypertension, and stroke. Studies showed the significant relationship between OSA and cardiac remodeling. The majority of investigations were focused on the left ventricle and its hypertrophy and function. Fewer studies investigated right ventricular structure and function revealing deteriorated diastolic and systolic function. Data regarding left and right...
Source: Heart Failure Reviews - February 2, 2020 Category: Cardiology Source Type: research

Renal implications of pulmonary arterial capacitance in acute heart failure with preserved ejection fraction.
Authors: Toroghi HM, Lo KB, Ziccardi MR, Horn B, Kanjanahattakij N, Malik E, Penalver J, Rangaswami J, Gupta S, Amanullah A Abstract Worsening renal function in patients with heart failure with preserved ejection fraction is associated with poor outcomes. Pulmonary arterial capacitance is a novel right heart catheterization derived hemodynamic metric representing pulmonary arterial tree distensibility and right ventricle afterload. Given the strong association between heart failure, pulmonary hypertension, and kidney function, the goal of this study is to investigate the correlation between Pulmonary arterial capac...
Source: Reviews in Cardiovascular Medicine - January 10, 2020 Category: Cardiology Tags: Rev Cardiovasc Med Source Type: research

Hospital outcomes in non-surgical patients identified at risk for OSA
ConclusionsFurther prospective studies are needed to understand the contribution of undiagnosed OSA to in-hospital respiratory outcomes.
Source: Heart and Lung: The Journal of Acute and Critical Care - December 24, 2019 Category: Respiratory Medicine Source Type: research

Prolargin and matrix metalloproteinase ‐2 in heart failure after heart transplantation and their association with haemodynamics
ConclusionsThe normalization pattern in HF patients of plasma prolargin and MMP ‐2 post‐HT towards controls' levels and their associations with improved haemodynamics indicate that prolargin and MMP‐2 may reflect, in part, the aberrant ECM remodelling involved in the pathophysiology of HF and associated PH. Their potential clinical use as biomarkers or targets for future therapy in HF and related PH remains to be investigated.
Source: ESC Heart Failure - December 18, 2019 Category: Cardiology Authors: Abdulla Ahmed, Salaheldin Ahmed, Mattias Arvidsson, Habib Bouzina, Jakob Lundgren, G öran Rådegran Tags: Original Research Article Source Type: research

Predictors of Unfavourable Outcomes in Children and Adolescents Submitted to Surgical Mitral Valvuloplasty Secondary to Chronic Rheumatic Heart Disease
Conclusion: The duration of vasoactive drug use is an independent predictor for unfavourable outcomes in the immed iate and late postoperative period, while residual mitral regurgitation was associated with reoperation, and both tricuspid regurgitation and pulmonary hypertension were associated with unfavourable outcomes.Resumo Fundamento: A plastia da valva mitral, em pacientes pedi átricos com cardiopatia reumática crônica, é superior à troca valvar e vem sendo utilizada com bons resultados. Objetivo: Identificar variáveis preditoras de desfecho desfavorável em crianças e adolescentes submetidos à valvoplastia m...
Source: Arquivos Brasileiros de Cardiologia - November 5, 2019 Category: Cardiology Source Type: research

Mitral Valve Repair in Young Rheumatic Patients
Conclusion: The duration of vasoactive drug use is an independent predictor for unfavourable outcomes in the immed iate and late postoperative period, while residual mitral regurgitation was associated with reoperation, and both tricuspid regurgitation and pulmonary hypertension were associated with unfavourable outcomes.Resumo Fundamento: A plastia da valva mitral, em pacientes pedi átricos com cardiopatia reumática crônica, é superior à troca valvar e vem sendo utilizada com bons resultados. Objetivo: Identificar variáveis preditoras de desfecho desfavorável em crianças e adolescentes submetidos à valvoplastia m...
Source: Arquivos Brasileiros de Cardiologia - November 5, 2019 Category: Cardiology Source Type: research

A rare cause of ischemic stroke: cardiac myxoma. Case report and review of literature.
Authors: Mustafa ER, Tudoraşcu DR, Giucă A, Toader DM, Foarfă MC, Puiu I, Istrate-Ofiţeru AM Abstract A 46-year-old female diagnosed several years ago with arterial hypertension and an ischemic stroke with significant recovery was admitted for dyspnea on usual physical activity and fatigue. Physical examination revealed signs of heart failure with crackles on both lung bases, distented jugular veins, accentuated pulmonic valve closure (P2) and tricuspid regurgitation murmur. Echocardiography identified a large tumor in the left atrium, suggestive of atrial myxoma, which caused a severe functional mitral stenosi...
Source: Romanian Journal of Morphology and Embryology - December 13, 2018 Category: General Medicine Tags: Rom J Morphol Embryol Source Type: research

Right Ventricular Stroke Work Index.
In conclusion, lower RVSWI was significantly associated with HF death or HF readmission in patients with PAH or CTEPH. PMID: 30101854 [PubMed - as supplied by publisher]
Source: International Heart Journal - August 15, 2018 Category: Cardiology Tags: Int Heart J Source Type: research

High Right Ventricular Stroke Work Index Is Associated with Worse Kidney Function in Patients with Heart Failure with Preserved Ejection Fraction
Conclusion: High right ventricular workload indicated by high RVSWI is associated with worse renal function in patients with Cpc-PH. Further prospective studies are needed to better understand this association.Cardiorenal Med 2018;8:123 –129
Source: Cardiorenal Medicine - February 28, 2018 Category: Urology & Nephrology Source Type: research

The Assessment of Right Ventricular Function by Right Ventricular Stroke Work Index in Patients with Pre-Capillary Pulmonary Hypertension
Background: Long-term outcomes of pre-capillary pulmonary hypertension (PH) have been improved. However, morbidity and mortality are still high because of right-sided heart failure (HF). Right-sided HF is closely related to right ventricular (RV) function such as RV stroke work index (RVSWI). The aim of this study was to compare clinical characteristics between low RVSWI and high RVSWI, and to investigate the association between low RVSWI and long-term outcomes in patients with pre-capillary PH.
Source: Journal of Cardiac Failure - September 20, 2017 Category: Cardiology Authors: Tatsuro Ibe, Hiroshi Wada, Yusuke Ugata, Yousuke Taniguchi, Kenichi Sakakura, Hideo Fujita, Shin-Ichi Momomura Source Type: research